SARS-CoV-2, like all RNA viruses, evolves and mutates. Since its discovery, the viral sequence for the novel coronavirus has accumulated a staggering number of mutations, giving rise to more virulent, transmissible and deadly variations that are taking hold across the globe. Since the virus can evolve, the assays designed to detect it must evolve as well.

The Fluidigm RT-PCR based Advanta® SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it.

Advanta SARS-CoV-2 Mutation Assay Panel